← Back to Clinical Trials
Recruiting NCT04571086

NCT04571086 FAPI-PET for Tumor Detection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04571086
Status Recruiting
Phase
Sponsor University Hospital, Essen
Condition Malignant Neoplasm
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2020-04-30
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2020-04-30 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI in patients receiving this imaging modality for tumor staging or restaging as part of clinical care.

Eligibility Criteria

Inclusion Criteria: 1. FAPI-PET scheduled for staging or restaging as part of clinical routine for proven or suspected malignancy 2. Age ≥ 18 years. Exclusion Criteria: 1. Patient cannot give consent for the study 2. Patient can not lie flat or tolerate FAPI PET imaging 3. Unwillingness or inability to comply with study and follow-up procedures 4. Condition of patient which is critical to participate in this study in the discretion of the investigators 5. Pregnant, lactating, or breast feeding women.

Contact & Investigator

Central Contact

Wolfgang Fendler, MD

✉ wolfgang.fendler@uk-essen.de

📞 +49 201 723 1862

Principal Investigator

Wolfgang Fendler, MD

PRINCIPAL INVESTIGATOR

University Hospital, Essen

Frequently Asked Questions

Who can join the NCT04571086 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Malignant Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04571086 currently recruiting?

Yes, NCT04571086 is actively recruiting participants. Contact the research team at wolfgang.fendler@uk-essen.de for enrollment information.

Where is the NCT04571086 trial being conducted?

This trial is being conducted at Essen, Germany.

Who is sponsoring the NCT04571086 clinical trial?

NCT04571086 is sponsored by University Hospital, Essen. The principal investigator is Wolfgang Fendler, MD at University Hospital, Essen. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology